Safety Data for Baricitinib Use in Children With Severe SARS-CoV-2 Infection
Baricitinib appears safe in children hospitalized for severe COVID-19. Most early baricitinib discontinuation for abnormal laboratory studies was secondary to provider caution.
Authors
- Sandra R. Arnold (ORCID: https://orcid.org/0000-0001-6130-8154)
- Becky McGee Landman
- Melissa Hines (ORCID: https://orcid.org/0000-0002-6646-6175)
- Diego R. Hijano (ORCID: https://orcid.org/0000-0002-2903-666X)
- Ted Morton (ORCID: https://orcid.org/0009-0008-3590-2086)
- Elspeth Bittle
Institutions
- St. Jude Children's Research Hospital (US)
- University of Tennessee Health Science Center (US)
- Le Bonheur Children's Hospital (US)
Publication Details
- Journal
- Hospital Pediatrics
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1542/hpeds.2024-008245
- Citations
- 3
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Pfizer
- Incyte
- Swedish Orphan Biovitrum